Mar 27, 2018
PTC Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH PLAINFIELD, N.J., March 27, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing a public offering of 4,000,000 shares of its common stock. All of the shares in the offering are to be sold by PTC. PTC intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 600,000 shares of common stock. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed.

Credit Suisse and Citigroup are acting as lead book-running managers for the offering. RBC Capital Markets is also acting as a book-running manager.

An automatically effective shelf registration statement on Form S-3 (the "Registration Statement") relating to the shares of common stock to be offered in the public offering has been filed with the Securities and Exchange Commission (the "SEC") and is available on the SEC's website at A preliminary prospectus supplement relating to and describing the terms of the offering is also being filed with the SEC and will be available on the SEC's website at Before investing in the offering, interested parties should read the preliminary prospectus supplement and the accompanying prospectus for the offering and the other documents PTC has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus, which provide more complete information about PTC and the offering. The offering will be made only by means of the prospectus supplement and the accompanying prospectus, forming a part of the Registration Statement. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email:; Citigroup Global Markets Inc., Broadridge Financial Solutions,1155 Long Island Avenue, Edgewood, NY 11717; telephone: (800)-831-9146; or RBC Capital Markets, LLC, Attention: Equity Syndicate , 200 Vesey Street, 8th Floor, New York, NY 10281.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. 

About PTC Therapeutics
PTC is a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Founded 20 years ago, PTC Therapeutics has successfully launched two rare disorder products and has a global commercial footprint. This success is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.

For More Information:

Emily Hill
+ 1 (908) 912-9327

Jane Baj
+1 (908) 912-9167

Cision View original content:

SOURCE PTC Therapeutics, Inc.